Secti',on of Comparative Medicine 377 in the "in vitro antigen" are not exactly factors I and II of the anthrax toxin. Thus, apart from the obvious fact that the "in vitro antigen" is non-toxic, this antigen when it acts as factor II will only increase the oedema production of an amount of factor I which has a small inherent effect; it will not, as does authentic factor II, form an oedema-producing mixture with a smaller and separately unreactive amount of factor I. Furthermore, the "in vitro antigen" has no synergic effect on factor II as regards cedema production (see Table II ).
INTRODUCTION
Prior to the introduction of S.19 vaccine to this country in 1941, a broth culture Br. abortus vaccine had been issued from Weybridge for many years. Under certain circumstances this vaccine was probably fairly efficient but its antigenic properties were unknown and it was rightly replaced by the S.19 vaccine.
Vaccination with S.19, an attenuated smooth strain (originally isolated by Cotton and Buck in 1923), had been started some years earlier in the United States and, by 1939, it had become firmly established there for the control of bovine brucellosis. The production of the liquid vaccine was begun at Weybridge with the assistance and advice of the United States Bureau of Animal Industry and output rapidly increased until an annual production of three-quarter million 5 ml. doses was attained. In 1944, the Ministry of Agriculture introduced the Calfhood Vaccination Scheme, whereby heifer calves from the age of 6 months to breeding age could be vaccinated at a small charge to the farmer by his own veterinary surgeon or by the staff of the Ministry. The scheme proved to be very successful and to-day over half of the vaccine issued is used for calfhood vaccination.
METHODS OF VACCINE PREPARATION In the preparation of the vaccine, care is taken to ensure that the smooth phase of the organism is always employed; the antigenicity of the vaccine is greatly reduced if dissociation is allowed to occur. For this reason the strain has always been cultivated on potato agar, although new techniques are now being evolved for production in a liquid medium; Roux flask culture is always laborious and the contamination risks are considerable. In 1956 the vaccine department at Weybridge moved into a new building equipped with the latest methods of ventilation for the production of a sterile atmosphere; the general improvements resulting from this have increased the yield by almost 20%.
Liquid culture techniques have been used by van Drimmelen (1956) at Onderstepoort for the production of S.19 vaccine. He has employed mechanical shaking of liquid cultures in large glass containers and, more recently (1957), the vortex system where 80 litres of liquid are revolved at 1,000 r.p.m. for seventy hours and a 2,000 to 6,000-fold increase in growth obtained. At Weybridge plans are now well forward to introduce experimentally the continuous culture system employed at Porton. In this apparatus there is a periodic flow of fresh liquid medium into a container which is mechanically stirred and supplied with sterile air through a sparger; the vaccine concentrate is drawn off at intervals at the rate of about one litre per hour.
FREEZE-DRYING OF S. 19 VACCINE
Freeze-dried S.19 vaccine has been produced in recent years by commercial laboratories. and others in several countries and in particular in the United States; the commercial undertakings have, quite understandably, not been prepared to divulge the medium used for thesuspension of organisms prior to freeze-drying. Skimmed milk is most frequently used as. the suspending medium but at Weybridge the re-suspending properties of this medium have not been satisfactory and the medium of Naylor and Smith (1946) (basically thiourea, dextrin and ascorbic acid) has been used instead. This medium has produced a satisfactory product which reconstitutes instantaneously; after freeze-drying the resultant viability is over 70% of the original count and the residual moisture is about 1 %.
To facilitate handling of the vaccine in the field, freeze-drying in glass-sealed ampoules has been avoided and rubber-stoppered bottles have been employed. A butyl rubber mix has been found which appears to be relatively impenetrable under vacuum to water vapour. The vaccine is dried with the rubber stopper in situ in the mouth of the bottle and a special two-pronged stopper has been developed for this purpose; the stopper is pushed home under vacuum when the drying cycle is completed.
The recommended concentration of viable organisms in S.19 vaccine at issue is 60 x 10à nd the minimal vaccinating dose is 25 x 10w; at Weybridge it has been considered advisable to employ a greater concentration than this and the corresponding figures are 80 x 109 and 40 x 109 respectively.
The object of freeze-drying S.19 vaccine is to retain its viability for as long as possible after drying. The "life" of the liquid vaccine is three months at 40 C. and, to be of any practical value, the duration of viability of the freeze-dried vaccine must be greatly in excess of this. It has been shown that dried vaccine will retain an issue viable count for nearly two years in the cold store and there seems to be no reason why this period should not be considerably extended. Tests on the viability of the vaccine at room temperature have been carried out after storage in the cold store for twelve months and a satisfactory count has been obtained up to the fourth week at room temperature. Counts on the vaccine stored at room temperature immediately after freeze-drying have indicated that a vaccinating dose can still be obtained up to the twelfth week compared with a maximum of four weeks in the liquid vaccine held under similar conditions.
Tests are now being performed on the dried vaccine under transportation conditions. Samples of vaccine have been distributed to various offices of the Ministry in Scotland and the West of England and have been returned at regular intervals for testing. Vaccine stored in the cold in these offices has retained a vaccinating dose for six months, which is the present extent to which the tests have been applied. Similar tests on an extended scale are now in hand and the vaccine is submitted to conditions similar to those to which it would be subjected in veterinary practice; the examination of returned samples has given encouraging results.
In a limited field trial a small number of calves and adult cows were vaccinated with the freeze-dried vaccine suspended in Smith-Naylor medium; no abnormal reactions were observed. The agglutinin response, ranging in titre from 1/40 to 1/320, followed the normal pattern of the liquid vaccine and the local reactions at the inoculation sites were not noticeably more severe. The temporary drop in milk yield which generally accompanies the use of liquid vaccine was also similar. To allow for the average 30 % loss of viability of the vaccine during the freeze-drying process, more vaccine concentrate is required and the various liquid culture processes already referred to may be of value in mass production techniques. Consideration will have to be given to the problem of the removal of the spent culture from the bacterial mass prior to freezedrying and its replacement with the suspending medium. Greater contamination risks in handling of the mass culture will be involved and there may be the added risk of loss in viability because it will not be possible to freeze the bacterial suspension so rapidly after harvesting and prior to freeze-drying.
APPLICATION OF THE VACCINE IN THE FIELD
McDiarmid (1957) has reported the results of a large experiment at Compton involving approximately 500 cattle and extending over seven years. Young cattle were vaccinated in groups: once at 6 months; once at 18 months; twice at 6 and 12 months; and three times at 6, 12 and 18 months. Cattle from each of these groups and controls were challenged with virulent Br. abortus, some at the I st pregnancy, some at the 2nd and so on up to and including 12, -the 5th pregnancy. The immunity did not apparently diminish over the five pregnancies, -irrespective of the method of vaccination employed. The triple vaccination gave a slightly better immunity than the single injection. Since, however, S.19 vaccine stimulates the production of agglutinins which cannot be distinguished from those resulting from natural infection, the single injection at 6 months of age is more desirable because the majority of animals vaccinated at that age return to the negative status by 18 months of age. The presence of agglutinins in the adult animal is disadvantageous for those who breed pedigree stock for sale or where it is desired to remove infected animals from a herd by blood testing. The use of a non-agglutinogenic vaccine is under investigation and this will presently be described.
The results of the Compton experiments show that one dose of S.19 vaccine at about 6 months of age will confer a satisfactory immunity against Br. abortus infection for at least live pregnancies.
ADJUVANT VACCINES (a) Br. abortus.-In the early days of S.19 production a non-agglutinogenic strain produced by McEwen and known as 45/20 was also used, particularly in adult cattle. Unfortunately it was found to undergo mutation and its use was discontinued. Interest has been reawakened in this strain recently since McEwen and Samuel (1955) showed that a heat-killed adjuvant vaccine prepared from this strain successfully immunized guinea-pigs. McDiarmid and Sutherland (1957) have subsequently compared the efficacy in guinea-pigs of living, heatkilled and dead adjuvant vaccines prepared from strains 19 and 45/20. Vaccine prepared with 'S.45/20 by any of these methods produced no agglutinins. Dead organisms of both strains suspended in Ringer gave poor protection; S.19 vaccine, both living in Ringer and dead in adjuvant, produced a slightly better protection rate than strain 45/20. The 45/20 adjuvant vaccine was slightly more effective than that prepared from the living suspension in Ringer.
The results of this trial have encouraged the Compton workers to begin an extended experiment on similar lines in cattle of breeding age. McDiarmid is of the opinion that the 45/20 adjuvant vaccine might be used as an adjunct to the present method of vaccination against brucellosis in cattle. It is suggested that, if the use of S.19 vaccine were eventually limited to calves of 6 months of age, the non-agglutinogenic S.45/20 vaccine could well be used in those herds where it was thought advantageous to vaccinate older animals also.
(b) Br. melitensis.-A somewhat similar situation now obtains with regard to the vaccination of goats against Br. melitensis. Renoux and his co-workers (1957) in Tunis have experimented with attenuated and adjuvant vaccines and the latest results show that a formolkilled vaccine prepared from a virulent strain of Br. melitensis suspended in a non-absorbable adjuvant gives a satisfactory immunity in goats for about six months.
Elberg and Faunce (1957) have shown that good protection can be obtained in pregnant goats by the use of a living strain of Br. melitensis which is smooth and avirulent; this is derived from a non-dependent mutant isolated from a streptomycin-dependent population. Its disadvantage is that, like S.19, it stimulates the production of agglutinins. Jones, Thomson and Alton (1958) at Weybridge have shown that an adjuvant vaccine derived from a killed rough culture of Br. melitensis produces the same immunity in guineapigs without producing agglutinins as a similar vaccine prepared from a smooth agglutinogenic strain. This work has now been carried a step farther by comparing the value of rough and smooth adjuvant vaccines in goats with the living smooth vaccine obtained from Elberg. The results have shown that there is not a significant difference between the three vaccines when challenged with graded doses of virulent Br. melitensis. The living vaccine of Elberg was most effective, however, in preventing a generalized infection with the larger doses of the virulent strain. Although this vaccine is agglutinogenic, it is anticipated that it will produce better immunity under field conditions than either of the dead vaccines. There is, therefore, a striking similarity between this vaccine and S.19 abortus vaccine in this respect.
CONCLUSION
To summarize, the campaign to control and eliminate bovine contagious abortion by the use of S.19 vaccine in Great Britain has given and continues to give satisfactory results. Approximately half a million heifer calves are vaccinated annually under the Calfhood Scheme and this single injection gives, in well over 90 % of cases, a satisfactory protection against infection for at least five pregnancies. The keeping qualities of the vaccine can be enhanced considerably by freeze-drying and it is anticipated that the vaccine will be issued as a freezedried product from Weybridge in the next few months. Work on mass liquid culture methods merits further investigation but vaccine derived from such a source might have to be subjected to a trial in cattle before one could be assured that it is entirely satisfactory as an immunizing agent.
Preliminary experiments on an adjuvant vaccine derived from the non-agglutinogenic strain 45/20 show considerable promise. The combination of these two vaccines with the VACCINATION with BCG has become established in many countries as an effective measure for the control of tuberculosis. There have been marked differences of opinion in this country as to the value of BCG vaccine, but the recent report of the Medical Research Council (1956) on vaccination of school leavers has shown it to have proved of value under certain conditions. A liquid vaccine was used in this trial-up to now the universally accepted form of BCG administration, except in Japan.
It has been realized that the liquid vaccine has certain disadvantages. First, the culture has to be closely watched for changes in antigenicity and virulence due to the continuous subculturing at tento fourteen-day intervals, and elaborate tests are necessary for this purpose. More important for the practical use of the vaccine are two other handicaps: it has only a limited life of about fourteen days and there is no direct evidence as to the antigenicity and safety of the vaccine when it is used. The vaccine consists of live bacteria and contains no antiseptics, so that slowly-growing contaminants would be difficult to detect by conventional sterility tests. The biological control of BCG is a long process. Apart from the safety tests, which include those for absence of virulence in the BCG, it is important to establish that the particular batch contains the required number of viable organisms. A much higher content is liable to produce untoward local reactions (ulcers, lymphadenitis); a low content may result in an unsatisfactory tuberculin conversion rate. Such variations in effect between batches of liquid vaccine have been noted.
It has been known that bacteria can be freeze-dried without affecting their biological characteristics, and it was obviously sensible to try to apply this technique to BCG, particularly in view of the considerable advances made in freeze-drying techniques as used in the preparation of antibiotics.
An effective freeze-dried BCG vaccine should have the following advantages over the liquid type: (a) Stability.-The vaccine would under suitable conditions be stable for at least one year and be available for use at any time during that period. (b) Uniformity.-The vaccine could be standardized in terms of viable bacteria, so avoiding undesirable variations between batches. (c) Safety and potency.-Each batch can be submitted to safety tests and to potency tests to establish its antigenicity before release.
GLAXO FREEZE-DRED BCG VACCINE A freeze-dried vaccine should be prepared in such a manner that it reconstitutes on addition of fluid to a homogeneous suspension of cells with a minimum of clumping. The medium in which the bacteria are dried should be non-antigenic and not liable to cause any reaction. In the past vaccines have been prepared in serum, 50 % glucose, 1 % sucrose, various concentrations of lactose, &c., but most of these have disadvantages. After prolonged trials we have chosen as a suspending agent an aqueous solution of 8-3 % of dextran with 7-5 % glucose. The vaccine (Ungar et al., 1956 ) is prepared from the same strain of BCG as that used in the M.R.C. trial; in our experience there is no essential difference in the strains of BCG used in various laboratories and freeze-dried vaccine can be prepared from any of them.
The strain is grown in a submerged culture in Sauton's medium, with addition of 1/4,000 w/v Triton "WR 1339", at a temperature of 370 C. for nine days. The growth is centrifuged and the deposit reconstituted in the dextran-glucose medium and standardized to a final con-
